This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
by Zacks Equity Research
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
by Zacks Equity Research
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
RCKT Stock Tanks on Patient Death in Danon Disease Study
by Zacks Equity Research
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
by Zacks Equity Research
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
by Zacks Equity Research
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
by Zacks Equity Research
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
by Zacks Equity Research
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
by Zacks Equity Research
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week
by Zacks Equity Research
Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates
by Zacks Equity Research
Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.